ClinicalTrials.gg
RecruitingNCT05295888TIUpdated Apr 24, 2025

Temporal Interference and Depression

An interventional study of Temporal Interference stimulation and Sham stimulation in Major Depressive Disorder, sponsored by Unity Health Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Depressive Disorder, Major by Unity Health Toronto — 8 open to participants now, 9 under way, none of them phase 3. Depressive Disorder, Major · Unity Health Toronto.

Planned enrollment
4th of 11
30 · median 30
Started
2025
with 3 others
No phase
7 of 17
5 open now
Registered
7th of 17
by date

Among the 17 studies in Depressive Disorder, Major by Unity Health Toronto, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, and was the 7th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

8 of the 17 studies in Depressive Disorder, Major by Unity Health Toronto are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depressive Disorder, Major by Unity Health Toronto, or all of them as a file.
02

Study summary

Major Depressive Disorder (MDD) has a high prevalence, is the leading cause of disability, and currently available interventions are associated with side effects and high treatment resistance. There is an urgent need for the development of novel interventions for MDD with alternate mechanisms of action. Temporal Interference (TI) stimulation is a newly emerging form of transcranial alternating current stimulation (tACS) that involves the application of two high-frequency currents at slightly different kHz frequencies. Since neurons, due to their intrinsic low-pass filtering, do not respond to high frequencies (i.e. > 100 Hz), TI relies on the 'beat' interaction leading to neuromodulation at any given location, resulting in a much smaller focus and allowing for better targeting. The subgenual cingulate cortex (SCC) appears to be critical in the pathophysiology of depression and treatment response, especially in treatment-resistant cases. Non-invasive treatments, however, are not able to accurately target SCC due to its deep location within the brain. In this trial, 30 participants meeting the diagnostic criteria for MDD will be randomized to receive 10 sessions of 130 Hz TI delivered daily for 30 minutes, or 10 sessions of sham stimulation. During the stimulation, participants will be watching emotional film clips to enhance target engagement. The investigators will collect metrics of SCC target engagement using the resting-state fMRI and EEG technologies, and determine feasibility, tolerability, safety, and therapeutic efficacy of TI stimulation in MDD. The results of this trial will inform the TI technology as a therapeutic tool for network-based psychiatric disorders, including MDD, and be vital for the design and development of a large-scale randomized-controlled trial.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Patients will be included if they:

  1. provide written before initiation of any study-related procedures
  2. are outpatients
  3. meet the criteria for major depressive disorder (MDD) with a current major depressive episode (MDE) without psychotic features as confirmed at Screening by the Mini International Neuropsychiatric Interview (MINI)
  4. are male or female, 18 to 65 years of age (inclusive) at screening
  5. have a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥ 20 (moderate to severe depression) at screening
  6. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
  7. able to adhere to the treatment schedule
  8. pass the TI adult safety screening questionnaire
  9. are able to understand and comply with the requirements of the study, as judged by the investigator(s)

Exclusion Criteria - Patients will be excluded if they:

  1. have an acute alcohol or substance use disorder, withdrawal symptoms requiring detoxification, or went through detoxification treatment (inpatient or outpatient) within 3 months before Screening, as obtained from MINI, Module I (Alcohol Use Disorder) and Module J (Substance Use Disorder, Non-Alcohol) assessed at Screening
  2. have a concomitant major unstable medical illness, active virus (HBV), virus (HPC), (HIV), active COVID-19 infection, cardiac pacemaker or implanted medication pump, as per medical history provided by the participant
  3. have active suicidal intent, confirmed by a 'Yes' response to Question B3 AND either Question B10 or B11, obtained from the MINI Suicidality, Module B (Suicidality), OR confirmed by the MADRS item #10 score ≥ 4, both assessed at Screening
  4. have a current clinical diagnosis of autism, dementia, or intellectual disability
  5. take medications prohibited by the protocol. Medications will be reviewed by the responsible MD
  6. are pregnant or lactating
  7. have any prior or current diagnosis of bipolar I or II disorder, MDD with psychotic features, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms as obtained from MINI, Module C (Manic and Hypomanic Episodes) and Module K (Psychotic Disorders and Mood Disorders with Psychotic Features) assessed at Screening
  8. have any prior or current diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), confirmed by MINI and assessed by a study investigator to be primary and causing greater impairment than MDD
  9. have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than MDD
  10. have received TI for any previous indication due to the potential compromise of subject blinding
  11. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space-occupying brain lesion, any history of seizure except those therapeutically induced by ECT or a febrile seizure of infancy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than 5 minutes, current history of poorly controlled migraines including chronic medication for migraine prevention
  12. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
  13. if participating in psychotherapy, have NOT been in stable treatment for at least 3 months prior to entry into the study or anticipate change in the frequency of therapeutic sessions or therapeutic focus over the duration of the study
  14. have a laboratory abnormality, in the opinion of one of the principal investigators or study physicians
  15. currently take medications that potentially limit the TI efficacy
  16. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with an interview)
  17. have a clinical finding that is unstable or that, in the opinion of the investigator(s), would be negatively affected by the study medication or that would affect the study medication (e.g., diabetes mellitus, hypertension, unstable angina)
  18. have uncorrected hypothyroidism or hyperthyroidism. Subjects needing a thyroid hormone supplement to treat hypothyroidism will be excluded if they have NOT been on a stable dose of the medication for 30 days prior to enrolment
  19. have any other condition that, in the opinion of the investigator(s), would adversely affect the subject's ability to complete the study or its measure
  20. wear a hairstyle or headdress at the time of the stimulation that prevents electrode contact with the scalp or would interfere with the stimulation (e.g., thick or curly hair)
  21. have any for receiving TI or undergoing MRI scans (e.g., hip circumference >180 cm or metal in the body)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    130Hz TI stimulation (total 30 min) + mood induction paradigm: ramp-up (30 sec) =\> stimulation (130Hz, 2mA per electrode pair, 4mA total, 29 min) =\> ramp-down (30 sec)

    Device: Temporal Interference stimulation

  • Sham comparator
    Sham Arm

    Sham stimulation (total 30 min) + mood induction paradigm: ramp-up (30 sec) =\> ramp-down (30 sec) =\> stimulation (130Hz, 0mA, 29 min)

    Device: Sham stimulation

Interventions

  • DeviceTemporal Interference stimulation

    TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.

  • DeviceSham stimulation

    Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.

06

What researchers measure

Primary outcomes

  1. Neuroimaging - Signal variance

    Signal variance within SCC to demonstrate SCC target engagement to TI stimulation

    Time frame: End of 2nd week of intervention

  2. Neuroimaging - Functional connectivity

    Seed-based resting-state functional connectivity of SCC to demonstrate SCC target engagement to TI stimulation

    Time frame: End of 2nd week of intervention

  3. Neuroimaging - Anatomical connectivity

    Anatomical connectivity of SCC to demonstrate SCC target engagement to TI stimulation

    Time frame: End of 2nd week of intervention

  4. Neuroimaging - Perfusion metrics

    Cerebral blood flow within SCC to demonstrate SCC target engagement to TI stimulation

    Time frame: End of 2nd week of intervention

Secondary outcomes

  1. Clinical change in depression symptoms

    Change in symptoms of depression measured by the 17-item Hamilton Depression Rating Scale (HAM-D); scores range from 0 to 53, and higher scores indicate more severe depression symptoms.

    Time frame: Baseline, end of 1st week of intervention, end of 2nd week of intervention, 1 week post-intervention, and 4 weeks post-intervention

  2. Clinical change in depression symptoms

    Change in symptoms of depression measured by the 16-item Quick Inventory of Depressive Symptomatology; scores range from 0 to 48, and higher scores indicate more severe depression symptoms.

    Time frame: Baseline, each intervention visit (5 times/week for 2 weeks), 1 week post-intervention, and 4 weeks post-intervention

  3. EEG Signals - Time domain features

    Changes in time domain features of gamma oscillation on resting-state EEG Changes in time domain features of theta oscillation on resting-state EEG

    Time frame: Baseline, end of 1st week of intervention, and end of 2nd week of intervention

  4. EEG Signals - Frequency domain features

    Changes in frequency domain features of gamma oscillation on resting-state EEG Changes in frequency domain features of theta oscillation on resting-state EEG

    Time frame: Baseline, end of 1st week of intervention, and end of 2nd week of intervention

  5. EEG Signals - Functional connectivity

    Changes in functional connectivity on resting-state EEG

    Time frame: Baseline, end of 1st week of intervention, and end of 2nd week of intervention

  6. Correlation between EEG and depression symptoms

    Correlation between changes in features of gamma or theta oscillations (EEG) and changes in depression symptoms measured by the HAM-D

    Time frame: Baseline, end of 1st week of intervention, and end of 2nd week of intervention

  7. EEG Signals - MMN event-related potential

    Changes in mismatch negativity (MMN) event-related potential amplitude and latency

    Time frame: Baseline, end of 1st week of intervention, and end of 2nd week of intervention

  8. Tolerability - Adverse events

    Incidence of treatment-emergent adverse events

    Time frame: End of 1st week of intervention, end of 2nd week of intervention, 1 week post-intervention, and 4 weeks post-intervention

  9. Trial Feasibility - Dropout rate

    The proportion of participants who discontinue participation in the study before completion

    Time frame: End of 1st week of intervention, end of 2nd week of intervention, 1 week post-intervention, and 4 weeks post-intervention

  10. Trial Feasibility - Recruitment rate

    The number of participants enrolled into the study per month

    Time frame: Enrollment

  11. Trial Feasibility - Intervention adherence

    Percentage of participants who completed ≥80% of scheduled intervention sessions

    Time frame: End of 2nd week of intervention

07

Study locations

1 of 1 sites recruiting
  • Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto
    Toronto, Ontario M5B 1W8, Canada
    Recruiting
    • Venkat Bhat, MD MSc · Contact416-864-2755
    • Venkat Bhat, MD MSc · Principal investigator
08

References and documents

Publications

  • Demchenko I, Rampersad S, Datta A, Horn A, Churchill NW, Kennedy SH, Krishnan S, Rueda A, Schweizer TA, Griffiths JD, Boyden ES, Santarnecchi E, Bhat V. Target engagement of the subgenual anterior cingulate cortex with transcranial temporal interference stimulation in major depressive disorder: a protocol for a randomized sham-controlled trial. Front Neurosci. 2024 Aug 29;18:1390250. doi: 10.3389/fnins.2024.1390250. eCollection 2024. PubMed 39268031 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Dec 2027, 31 months later.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 31 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Mar 25, 2022
StartEst.
May 15, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05295888
Collaborators
Beth Israel Deaconess Medical Center, Northeastern University, Centre for Addiction and Mental Health, Charite University, Berlin, Germany, Toronto Metropolitan University
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
May 15, 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 24, 2025

Study contacts

Venkat Bhat, MD MSc
Contact
Venkat.Bhat@unityhealth.to
416-360-4000 ext. 76404
Ilya Demchenko, MSc
Contact
Ilya.Demchenko@unityhealth.to
416-360-4000 ext. 77062
Venkat Bhat, MD MSc
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion